RxDoctor Payments Data

Jeryl Pittman

Primary Care · Richmond, KYNPI 1891990479

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,450 and has fallen 50.7% since, to $715 in 2025. Among primary care clinicians in KY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,704in general payments, 2019–2025

Across 337 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$754
  • Vanda Pharmaceuticals Inc.$555
  • AbbVie$523
  • GSK$454
  • Novo Nordisk$400
  • Amgen$377
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,704 in reported general payments places this provider in the 90th percentile of 80 primary care providers in Kentucky.

See all primary care providers in Kentucky

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$50,132
MounjaroTirzepatide35$48,589
JardianceEmpagliflozin40$40,959
OzempicSemaglutide26$31,373
Tresiba Flextouch U-200Insulin Degludec22$27,232
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$26,695
FarxigaDapagliflozin Propanediol27$24,225
LinzessLinaclotide25$20,602
Janumet XrSitagliptin Phos/Metformin Hcl33$16,865
TrulancePlecanatide25$15,717
MyrbetriqMirabegron13$9,619
SynjardyEmpagliflozin/Metformin Hcl12$8,725
CreonLipase/Protease/Amylase12$7,137
Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp12$4,946
BelsomraSuvorexant11$4,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$161$50,13251 claims
Boehringer IngelheimJardiance, Synjardy$39$49,68552 claims
Lilly USA, LLCMounjaro$754$48,58935 claims
Novo NordiskOzempic$400$31,37326 claims
AbbVieLinzess, Creon, Synthroid$523$29,07353 claims
AstraZenecaFarxiga, Symbicort$95$27,36039 claims
GSKTrelegy Ellipta$454$26,69528 claims
MerckJanumet Xr, Belsomra$78$21,77444 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$149$15,71725 claims
Astellas Pharma US IncMyrbetriq$84$9,61913 claims
Almatica Pharma LLCLoreev Xr$159$4,84912 claims
Arbor Pharmaceuticals, Inc.Edarbi$32$4,56812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 80 primary care providers in Kentucky.

Other primary care in Richmond

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →